Hwang Sungsoon, Kang Se Woong, Choi Jaehwan, Park Kyung-Ah, Lim Dong Hui, Shin Ju-Young, Kang Danbee, Cho Juhee, Kim Sang Jin
Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H., S.W.K., J.C., K.-A.P., D.H.L., S.J.K.), Seoul, Republic of Korea; Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University (S.H., D.H.L., J.-Y.S., D.K., J.C.), Seoul, Republic of Korea.
Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H., S.W.K., J.C., K.-A.P., D.H.L., S.J.K.), Seoul, Republic of Korea.
Am J Ophthalmol. 2025 Jan;269:69-77. doi: 10.1016/j.ajo.2024.08.015. Epub 2024 Aug 22.
This study aimed to assess the risk of ocular adverse events, including retinal artery occlusion (RAO), retinal vein occlusion (RVO), noninfectious uveitis (NIU), noninfectious scleritis (NIS), optic neuritis (ON), ischemic optic neuropathy (ION), and ocular motor cranial nerve palsy (OMCNP), following Coronavirus Disease 2019 (COVID-19) vaccination.
Population-based self-controlled case series METHODS: This study utilized nationwide claims and vaccination data provided by the Korea National Health Insurance Service and Korea Disease Control and Prevention Agency. From the entire South Korean population of 52 million individuals, patients with incident RAO, RVO, anterior NIU, nonanterior NIU, NIS, ON, ION, or OMCNP between January 2021 and March 2022 were included. The postvaccination risk period was defined as up to 56 days after COVID-19 vaccination. The relative incidence rate ratios (IRRs) for RAO, RVO, anterior NIU, nonanterior NIU, NIS, ON, ION, and OMCNP during the risk periods were measured using conditional Poisson regression.
The study included 6,590, 70,120, 137,958, 17,921, 15,492, 2,039, 49,089, and 11,312 cases of incident RAO, RVO, anterior NIU, nonanterior NIU, NIS, ON, ION, and OMCNP, respectively. The IRRs (95% confidence interval) during the early risk period (0-28 days) were 0.95 (0.88-1.01), 0.96 (0.94-0.98), 0.93 (0.91-0.94), 0.93 (0.89-0.96), 0.96 (0.92-1.01), 1.04 (0.92-1.18), 0.98 (0.95-1.00), and 0.91 (0.86-0.96), respectively. In the late risk period (29-56 days), the IRRs were 0.96 (0.89-1.03), 0.93 (0.91-0.96), 0.96 (0.95-0.98), 1.00 (0.95-1.04), 0.96 (0.91-1.01), 1.00 (0.87-1.15), 1.01 (0.98-1.04), and 0.95 (0.90-1.01), respectively.
COVID-19 vaccination did not increase the risk of incident RAO, RVO, anterior NIU, nonanterior NIU, NIS, ON, ION, or OMCNP during the postvaccination period.
本研究旨在评估2019年冠状病毒病（COVID-19）疫苗接种后眼部不良事件的风险，包括视网膜动脉阻塞（RAO）、视网膜静脉阻塞（RVO）、非感染性葡萄膜炎（NIU）、非感染性巩膜炎（NIS）、视神经炎（ON）、缺血性视神经病变（ION）和动眼神经麻痹（OMCNP）。
基于人群的自我对照病例系列
本研究利用了韩国国民健康保险服务局和韩国疾病控制与预防机构提供的全国性索赔和疫苗接种数据。在2021年1月至2022年3月期间，从韩国5200万总人口中纳入了发生RAO、RVO、前部NIU、非前部NIU、NIS、ON、ION或OMCNP的患者。疫苗接种后的风险期定义为COVID-19疫苗接种后长达56天。使用条件泊松回归测量风险期内RAO、RVO、前部NIU、非前部NIU、NIS、ON、ION和OMCNP的相对发病率比（IRR）。
该研究分别纳入了6590例、70120例、137958例、17921例、15492例、2039例、49089例和11312例新发RAO、RVO、前部NIU、非前部NIU、NIS、ON、ION和OMCNP病例。早期风险期（0-28天）的IRR（95%置信区间）分别为0.95（0.88-1.01）、0.96（0.94-0.98）、0.93（0.91-0.94）、0.93（0.89-0.96）、0.96（0.92-1.01）、1.04（0.92-1.18）、0.98（0.95-1.00）和0.91（0.86-0.96）。在晚期风险期（29-56天），IRR分别为0.96（0.89-1.03）、0.93（0.91-0.96）、0.96（0.95-0.98）、1.00（0.95-1.04）、0.96（0.91-1.01）、1.00（0.87-1.15）、1.01（0.98-1.04）和0.95（0.90-1.01）。
COVID-19疫苗接种在接种后期间并未增加新发RAO、RVO、前部NIU、非前部NIU、NIS、ON、ION或OMCNP的风险。
